Notwithstanding the equivocal evidence for benefit from GLP‐1/GIP co‐infusion studies, unimolecular GLP1R/GIPR dual agonists have been developed with promising pre‐clinical results (enhanced weight loss, improved glycaemia, reduced hepatosteatosis) in animal models.82 One recent study has reported the Phase 2A clinical trial results of one such dual agonist, NNC0090‐2746, which possesses balanced affinities for the GIPR and the GLP1R.83 A 1.8 mg once‐daily dose was administered to 96 overweight/obese patients with type 2 diabetes. Here, GIP is linked to type 2 diabetes mellitus.